HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept
{
"count": 1455223,
"next": "https://lda.senate.gov/api/v1/filings/?format=api&ordering=-client__name&page=4&page_size=25%5Cn%5C",
"previous": "https://lda.senate.gov/api/v1/filings/?format=api&ordering=-client__name&page=2&page_size=25%5Cn%5C",
"results": [
{
"url": "https://lda.senate.gov/api/v1/filings/06c98791-3159-4870-8a16-a53a185e8ba9/?format=api",
"filing_uuid": "06c98791-3159-4870-8a16-a53a185e8ba9",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2019,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/06c98791-3159-4870-8a16-a53a185e8ba9/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Will Le",
"dt_posted": "2020-01-21T10:28:11.907000-05:00",
"termination_date": null,
"registrant": {
"id": 55291,
"url": "https://lda.senate.gov/api/v1/registrants/55291/?format=api",
"house_registrant_id": 35132,
"name": "BUCHANAN INGERSOLL & ROONEY, PC",
"description": "law firm",
"address_1": "1700 K Street, NW",
"address_2": "Suite 300",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20006",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-05-11T19:02:25.306258-04:00"
},
"client": {
"id": 159682,
"url": "https://lda.senate.gov/api/v1/clients/159682/?format=api",
"client_id": 1005317,
"name": "ZYNERBA PHARMACEUTICALS, INC.",
"general_description": "pharmaceutical",
"client_government_entity": false,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2015-02-01"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Raise awareness of synthetic CBD for research and hemp legislation; Advocate for inclusion of synthetic CBD in Farm Bill or other legislation",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 61183,
"prefix": null,
"prefix_display": null,
"first_name": "ELIZABETH",
"nickname": null,
"middle_name": null,
"last_name": "WESTBROOK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
},
{
"lobbyist": {
"id": 43567,
"prefix": "mr",
"prefix_display": "MR.",
"first_name": "EDWARD",
"nickname": null,
"middle_name": "JOHN",
"last_name": "ALLERA",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
},
{
"lobbyist": {
"id": 58343,
"prefix": "mr",
"prefix_display": "MR.",
"first_name": "MICHAEL",
"nickname": null,
"middle_name": "P",
"last_name": "STRAZZELLA",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "PHA",
"general_issue_code_display": "Pharmacy",
"description": "Raise awareness of synthetic CBD for research and hemp legislation",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 61183,
"prefix": null,
"prefix_display": null,
"first_name": "ELIZABETH",
"nickname": null,
"middle_name": null,
"last_name": "WESTBROOK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
},
{
"lobbyist": {
"id": 43567,
"prefix": "mr",
"prefix_display": "MR.",
"first_name": "EDWARD",
"nickname": null,
"middle_name": "JOHN",
"last_name": "ALLERA",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
},
{
"lobbyist": {
"id": 58343,
"prefix": "mr",
"prefix_display": "MR.",
"first_name": "MICHAEL",
"nickname": null,
"middle_name": "P",
"last_name": "STRAZZELLA",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/762e7a69-5af6-4583-98ea-884a8774945d/?format=api",
"filing_uuid": "762e7a69-5af6-4583-98ea-884a8774945d",
"filing_type": "Q3",
"filing_type_display": "3rd Quarter - Report",
"filing_year": 2016,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/762e7a69-5af6-4583-98ea-884a8774945d/print/",
"filing_document_content_type": "text/html",
"income": "20000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2016-10-20T16:33:18.140000-04:00",
"termination_date": null,
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [
{
"general_issue_code": "BUD",
"general_issue_code_display": "Budget/Appropriations",
"description": "H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/22204c8d-bc0a-40fb-b30d-30dce6522580/?format=api",
"filing_uuid": "22204c8d-bc0a-40fb-b30d-30dce6522580",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2016,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/22204c8d-bc0a-40fb-b30d-30dce6522580/print/",
"filing_document_content_type": "text/html",
"income": "20000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2017-01-19T16:20:07-05:00",
"termination_date": null,
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Medical research for PTSD.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "BUD",
"general_issue_code_display": "Budget/Appropriations",
"description": "H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/841b7de1-c529-467f-a57e-213f6d3ef441/?format=api",
"filing_uuid": "841b7de1-c529-467f-a57e-213f6d3ef441",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2016,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/841b7de1-c529-467f-a57e-213f6d3ef441/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2016-04-20T18:10:01.170000-04:00",
"termination_date": null,
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [
{
"general_issue_code": "BUD",
"general_issue_code_display": "Budget/Appropriations",
"description": "H.R. __ / S. ___ - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/0f840df8-aafd-4737-b4fd-ffbb786f8193/?format=api",
"filing_uuid": "0f840df8-aafd-4737-b4fd-ffbb786f8193",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2016,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/0f840df8-aafd-4737-b4fd-ffbb786f8193/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2016-04-20T11:28:55-04:00",
"termination_date": null,
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [
{
"general_issue_code": "BUD",
"general_issue_code_display": "Budget/Appropriations",
"description": "H.R. __ / S. ___ - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/b30111d8-3fa2-4d77-9459-2328f54cc542/?format=api",
"filing_uuid": "b30111d8-3fa2-4d77-9459-2328f54cc542",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2016,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/b30111d8-3fa2-4d77-9459-2328f54cc542/print/",
"filing_document_content_type": "text/html",
"income": "20000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2016-07-20T15:03:25.540000-04:00",
"termination_date": null,
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [
{
"general_issue_code": "BUD",
"general_issue_code_display": "Budget/Appropriations",
"description": "H.R. __ / S. ___ - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 64541,
"prefix": null,
"prefix_display": null,
"first_name": "JULIE",
"nickname": null,
"middle_name": "P.",
"last_name": "PAWELCZYK",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/8a99e99a-6752-48bc-93db-e6296ccbb598/?format=api",
"filing_uuid": "8a99e99a-6752-48bc-93db-e6296ccbb598",
"filing_type": "1TY",
"filing_type_display": "1st Quarter - Termination (No Activity)",
"filing_year": 2017,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/8a99e99a-6752-48bc-93db-e6296ccbb598/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Julie Pawelczyk",
"dt_posted": "2017-04-20T13:52:54.257000-04:00",
"termination_date": "2017-01-16",
"registrant": {
"id": 401004840,
"url": "https://lda.senate.gov/api/v1/registrants/401004840/?format=api",
"house_registrant_id": null,
"name": "THE CONAFAY GROUP, LLC",
"description": "Life Sciences Consulting firm",
"address_1": "2200 Pennsylvania Ave, NW",
"address_2": "4th Floor East",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": "20037",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ALEXANDRA MODLY",
"contact_telephone": "+1 202-507-5703",
"dt_updated": "2021-05-27T19:26:19.399567-04:00"
},
"client": {
"id": 196754,
"url": "https://lda.senate.gov/api/v1/clients/196754/?format=api",
"client_id": 202,
"name": "ZYNERBA PHARMACEUTICALS",
"general_description": "Pharmaceutical and therapeutic company.",
"client_government_entity": true,
"client_self_select": null,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2016-03-10"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/4108d8a3-2c60-4ba2-b320-039ff81c72d5/?format=api",
"filing_uuid": "4108d8a3-2c60-4ba2-b320-039ff81c72d5",
"filing_type": "YY",
"filing_type_display": "Year-End Report",
"filing_year": 2007,
"filing_period": "year_end",
"filing_period_display": "Year-End (July 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/4108d8a3-2c60-4ba2-b320-039ff81c72d5/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2008-02-06T14:33:15.370000-05:00",
"termination_date": null,
"registrant": {
"id": 4117,
"url": "https://lda.senate.gov/api/v1/registrants/4117/?format=api",
"house_registrant_id": 30920,
"name": "APCO WORLDWIDE LLC",
"description": "Public relations and strategic communications.",
"address_1": "1299 Pennsylvania Avenue, NW",
"address_2": "Suite 300",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-04-17T19:02:24.813311-04:00"
},
"client": {
"id": 103910,
"url": "https://lda.senate.gov/api/v1/clients/103910/?format=api",
"client_id": 1002690,
"name": "ZYMOGENETICS",
"general_description": "Biotechnology/ pharmaceutical company",
"client_government_entity": false,
"client_self_select": false,
"state": null,
"state_display": null,
"country": "",
"country_display": "* Undetermined",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "",
"ppb_country_display": "* Undetermined",
"effective_date": "2007-08-14"
},
"lobbying_activities": [
{
"general_issue_code": "GOV",
"general_issue_code_display": "Government Issues",
"description": "Patent reform",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Follow-on biologics",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/4ec41593-fa90-48a2-902c-2b1ef83cfc7f/?format=api",
"filing_uuid": "4ec41593-fa90-48a2-902c-2b1ef83cfc7f",
"filing_type": "Q4Y",
"filing_type_display": "4th Quarter - Report (No Activity)",
"filing_year": 2009,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/4ec41593-fa90-48a2-902c-2b1ef83cfc7f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2010-01-13T15:48:29.293000-05:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/13cc355a-f31e-4f12-a824-5f067ee3fdd9/?format=api",
"filing_uuid": "13cc355a-f31e-4f12-a824-5f067ee3fdd9",
"filing_type": "1T",
"filing_type_display": "1st Quarter - Termination",
"filing_year": 2008,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/13cc355a-f31e-4f12-a824-5f067ee3fdd9/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Lynley A. Ogilvie, associate general counsel",
"dt_posted": "2008-04-16T16:51:31-04:00",
"termination_date": "2008-03-01",
"registrant": {
"id": 4117,
"url": "https://lda.senate.gov/api/v1/registrants/4117/?format=api",
"house_registrant_id": 30920,
"name": "APCO WORLDWIDE LLC",
"description": "Public relations and strategic communications.",
"address_1": "1299 Pennsylvania Avenue, NW",
"address_2": "Suite 300",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-04-17T19:02:24.813311-04:00"
},
"client": {
"id": 103910,
"url": "https://lda.senate.gov/api/v1/clients/103910/?format=api",
"client_id": 1002690,
"name": "ZYMOGENETICS",
"general_description": "Biotechnology/ pharmaceutical company",
"client_government_entity": false,
"client_self_select": false,
"state": null,
"state_display": null,
"country": "",
"country_display": "* Undetermined",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "",
"ppb_country_display": "* Undetermined",
"effective_date": "2007-08-14"
},
"lobbying_activities": [
{
"general_issue_code": "GOV",
"general_issue_code_display": "Government Issues",
"description": "Patent reform.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Legislative Staff, Congressman Tom Foley",
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Follow-on biologics.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Legislative Staff, Congressman Tom Foley",
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/b767345e-ab3f-4323-9fca-3eb5d27ffd7e/?format=api",
"filing_uuid": "b767345e-ab3f-4323-9fca-3eb5d27ffd7e",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2007,
"filing_period": "year_end",
"filing_period_display": "Year-End (July 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/b767345e-ab3f-4323-9fca-3eb5d27ffd7e/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2007-06-28T17:57:21-04:00",
"termination_date": null,
"registrant": {
"id": 4117,
"url": "https://lda.senate.gov/api/v1/registrants/4117/?format=api",
"house_registrant_id": 30920,
"name": "APCO WORLDWIDE LLC",
"description": "Public relations and strategic communications.",
"address_1": "1299 Pennsylvania Avenue, NW",
"address_2": "Suite 300",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-04-17T19:02:24.813311-04:00"
},
"client": {
"id": 103910,
"url": "https://lda.senate.gov/api/v1/clients/103910/?format=api",
"client_id": 1002690,
"name": "ZYMOGENETICS",
"general_description": "Biotechnology/ pharmaceutical company",
"client_government_entity": false,
"client_self_select": false,
"state": null,
"state_display": null,
"country": "",
"country_display": "* Undetermined",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "",
"ppb_country_display": "* Undetermined",
"effective_date": "2007-08-14"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Patent reform",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/f2a19c16-5bc3-4ea0-96c7-b5c6abc11279/?format=api",
"filing_uuid": "f2a19c16-5bc3-4ea0-96c7-b5c6abc11279",
"filing_type": "3TY",
"filing_type_display": "3rd Quarter - Termination (No Activity)",
"filing_year": 2010,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/f2a19c16-5bc3-4ea0-96c7-b5c6abc11279/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2010-10-14T17:46:22.400000-04:00",
"termination_date": "2010-09-30",
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/4ae40b64-0f87-4962-a456-095a74931371/?format=api",
"filing_uuid": "4ae40b64-0f87-4962-a456-095a74931371",
"filing_type": "Q3Y",
"filing_type_display": "3rd Quarter - Report (No Activity)",
"filing_year": 2009,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/4ae40b64-0f87-4962-a456-095a74931371/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2009-10-08T15:29:02-04:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/c98a9f79-3209-4a27-a77e-b9426786d42a/?format=api",
"filing_uuid": "c98a9f79-3209-4a27-a77e-b9426786d42a",
"filing_type": "MM",
"filing_type_display": "Mid-Year Report",
"filing_year": 2007,
"filing_period": "mid_year",
"filing_period_display": "Mid-Year (Jan 1 - Jun 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/c98a9f79-3209-4a27-a77e-b9426786d42a/print/",
"filing_document_content_type": "application/pdf",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": null,
"dt_posted": "2007-08-14T17:55:35-04:00",
"termination_date": null,
"registrant": {
"id": 4117,
"url": "https://lda.senate.gov/api/v1/registrants/4117/?format=api",
"house_registrant_id": 30920,
"name": "APCO WORLDWIDE LLC",
"description": "Public relations and strategic communications.",
"address_1": "1299 Pennsylvania Avenue, NW",
"address_2": "Suite 300",
"address_3": null,
"address_4": null,
"city": "Washington",
"state": "DC",
"state_display": "District of Columbia",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "",
"contact_telephone": "",
"dt_updated": "2021-04-17T19:02:24.813311-04:00"
},
"client": {
"id": 103910,
"url": "https://lda.senate.gov/api/v1/clients/103910/?format=api",
"client_id": 1002690,
"name": "ZYMOGENETICS",
"general_description": "Biotechnology/ pharmaceutical company",
"client_government_entity": false,
"client_self_select": false,
"state": null,
"state_display": null,
"country": "",
"country_display": "* Undetermined",
"ppb_state": null,
"ppb_state_display": null,
"ppb_country": "",
"ppb_country_display": "* Undetermined",
"effective_date": "2007-08-14"
},
"lobbying_activities": [
{
"general_issue_code": "GOV",
"general_issue_code_display": "Government Issues",
"description": "Patent reform",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Follow-on biologics",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 17083,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "N/A",
"new": null
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/f9bd42f1-7962-4633-bc31-0df6d5b7c844/?format=api",
"filing_uuid": "f9bd42f1-7962-4633-bc31-0df6d5b7c844",
"filing_type": "RR",
"filing_type_display": "Registration",
"filing_year": 2009,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/f9bd42f1-7962-4633-bc31-0df6d5b7c844/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2009-05-13T14:41:08-04:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Medicare & Medicaid policy changes\nHealth care reform\nPatent Reform Legislation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 45967,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Rep. Jay Inslee",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Medicare & Medicaid policy changes\nHealth care reform\nPatent Reform Legislation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 45967,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Rep. Jay Inslee",
"new": true
}
],
"government_entities": []
},
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Medicare & Medicaid policy changes\nHealth care reform\nPatent Reform Legislation",
"foreign_entity_issues": null,
"lobbyists": [
{
"lobbyist": {
"id": 45967,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Rep. Jay Inslee",
"new": true
}
],
"government_entities": []
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/28f943fd-fc2e-455e-a77c-8623c7f7cac6/?format=api",
"filing_uuid": "28f943fd-fc2e-455e-a77c-8623c7f7cac6",
"filing_type": "Q1Y",
"filing_type_display": "1st Quarter - Report (No Activity)",
"filing_year": 2010,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/28f943fd-fc2e-455e-a77c-8623c7f7cac6/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2010-04-16T11:57:47.083000-04:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/61e08069-862d-4055-b704-ef49fb66626a/?format=api",
"filing_uuid": "61e08069-862d-4055-b704-ef49fb66626a",
"filing_type": "Q2",
"filing_type_display": "2nd Quarter - Report",
"filing_year": 2009,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/61e08069-862d-4055-b704-ef49fb66626a/print/",
"filing_document_content_type": "text/html",
"income": "5000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2009-07-10T17:36:17-04:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Patent Reform Legislation",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 45967,
"prefix": null,
"prefix_display": null,
"first_name": "JAKE",
"nickname": null,
"middle_name": null,
"last_name": "JOHNSTON",
"suffix": null,
"suffix_display": null
},
"covered_position": "Legislative Director, Rep. Jay Inslee",
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/dac4ad57-c2bb-4f12-957d-2edef487b23e/?format=api",
"filing_uuid": "dac4ad57-c2bb-4f12-957d-2edef487b23e",
"filing_type": "Q2Y",
"filing_type_display": "2nd Quarter - Report (No Activity)",
"filing_year": 2010,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/dac4ad57-c2bb-4f12-957d-2edef487b23e/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Jake Johnston, President",
"dt_posted": "2010-07-13T13:28:38.513000-04:00",
"termination_date": null,
"registrant": {
"id": 400383768,
"url": "https://lda.senate.gov/api/v1/registrants/400383768/?format=api",
"house_registrant_id": null,
"name": "JOHNSTON GROUP, LLC",
"description": "Public affairs consulting firm",
"address_1": "2400 NW 80th Street",
"address_2": "#191",
"address_3": null,
"address_4": null,
"city": "Seattle",
"state": "WA",
"state_display": "Washington",
"zip": "98117",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "JAKE JOHNSTON",
"contact_telephone": "+1 206-240-3133",
"dt_updated": "2021-05-18T19:02:27.706330-04:00"
},
"client": {
"id": 189827,
"url": "https://lda.senate.gov/api/v1/clients/189827/?format=api",
"client_id": 87,
"name": "ZYMOGENETICS",
"general_description": "Biopharmaceutical developer and manufacturer",
"client_government_entity": true,
"client_self_select": false,
"state": "WA",
"state_display": "Washington",
"country": "US",
"country_display": "United States of America",
"ppb_state": "WA",
"ppb_state_display": "Washington",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2009-05-11"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/deb80fe1-0821-4b00-b5c8-6eb4126ab21f/?format=api",
"filing_uuid": "deb80fe1-0821-4b00-b5c8-6eb4126ab21f",
"filing_type": "Q3",
"filing_type_display": "3rd Quarter - Report",
"filing_year": 2017,
"filing_period": "third_quarter",
"filing_period_display": "3rd Quarter (July 1 - Sep 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/deb80fe1-0821-4b00-b5c8-6eb4126ab21f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "143000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2017-10-23T15:53:41.300000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues\nS. 1049, provisions related to physician education on abuse-deterrent opioid products",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 12,
"name": "White House Office"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/cf1b0c39-b925-42bd-b037-10c532ddbfe8/?format=api",
"filing_uuid": "cf1b0c39-b925-42bd-b037-10c532ddbfe8",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2017,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/cf1b0c39-b925-42bd-b037-10c532ddbfe8/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "140000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Paul Varki",
"dt_posted": "2017-04-19T17:20:30.473000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids\nProvisions related to the reauthorization of the Prescription Drug User Fee Act\n1st Amendment/Communications with payors/off-label policy issues\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "CPT",
"general_issue_code_display": "Copyright/Patent/Trademark",
"description": "Provisions related to abuse-deterrent opioid exclusivity",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "Issues related to DEA quotas of Schedule I and II controlled substances\nS. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/e27f6fde-67f9-405a-9143-6c828b2ba7a7/?format=api",
"filing_uuid": "e27f6fde-67f9-405a-9143-6c828b2ba7a7",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2017,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/e27f6fde-67f9-405a-9143-6c828b2ba7a7/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "143000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-01-11T11:29:16.237000-05:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/30eb5997-d604-4340-9c68-9b8fa2dda83f/?format=api",
"filing_uuid": "30eb5997-d604-4340-9c68-9b8fa2dda83f",
"filing_type": "Q2Y",
"filing_type_display": "2nd Quarter - Report (No Activity)",
"filing_year": 2019,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/30eb5997-d604-4340-9c68-9b8fa2dda83f/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-07-15T09:00:06.210000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/93d2b8fa-e651-4355-b621-c1d33cd152af/?format=api",
"filing_uuid": "93d2b8fa-e651-4355-b621-c1d33cd152af",
"filing_type": "Q1",
"filing_type_display": "1st Quarter - Report",
"filing_year": 2018,
"filing_period": "first_quarter",
"filing_period_display": "1st Quarter (Jan 1 - Mar 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/93d2b8fa-e651-4355-b621-c1d33cd152af/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": "178000.00",
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Megan Timmins",
"dt_posted": "2018-04-20T13:37:20.173000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [
{
"general_issue_code": "MMM",
"general_issue_code_display": "Medicare/Medicaid",
"description": "Prescription drug abuse policy issues\nProvisions related to abuse-deterrent opioid formulary placement\nProvisions related to abuse-deterrent opioid coverage and access in Medicare",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "ALC",
"general_issue_code_display": "Alcohol and Drug Abuse",
"description": "S. 524 (114th Congress): Provisions related to opioid treatment and abuse",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
},
{
"general_issue_code": "HCR",
"general_issue_code_display": "Health Issues",
"description": "Prescription drug abuse and misuse policy issues\nH.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids\nH.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology\nH.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids\nAbuse-deterrent opioid policy issues\nPain therapy access policy issues",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 66526,
"prefix": null,
"prefix_display": null,
"first_name": "CARA",
"nickname": null,
"middle_name": "D",
"last_name": "MOON",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 136,
"name": "Centers For Medicare and Medicaid Services (CMS)"
},
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/57e47cf0-6d01-4d8d-b40d-7949f977e829/?format=api",
"filing_uuid": "57e47cf0-6d01-4d8d-b40d-7949f977e829",
"filing_type": "4TY",
"filing_type_display": "4th Quarter - Termination (No Activity)",
"filing_year": 2019,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/57e47cf0-6d01-4d8d-b40d-7949f977e829/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "Madeline Scherwitzky",
"dt_posted": "2020-01-16T09:38:43.133000-05:00",
"termination_date": "2019-10-01",
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
},
{
"url": "https://lda.senate.gov/api/v1/filings/ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73/?format=api",
"filing_uuid": "ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73",
"filing_type": "Q2Y",
"filing_type_display": "2nd Quarter - Report (No Activity)",
"filing_year": 2019,
"filing_period": "second_quarter",
"filing_period_display": "2nd Quarter (Apr 1 - June 30)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/ffc4b0b4-0cec-4c30-aa73-e7eae0b9ce73/print/",
"filing_document_content_type": "text/html",
"income": null,
"expenses": null,
"expenses_method": "c",
"expenses_method_display": "Method C - Reporting amounts under section 162(e) of the Internal Revenue Code",
"posted_by_name": "E. Blair Clark-Schoeb",
"dt_posted": "2019-07-12T14:46:24.230000-04:00",
"termination_date": null,
"registrant": {
"id": 401104361,
"url": "https://lda.senate.gov/api/v1/registrants/401104361/?format=api",
"house_registrant_id": null,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"description": "Specialty Pharmaceutical Company",
"address_1": "600 LEE ROAD SUITE 100",
"address_2": null,
"address_3": null,
"address_4": null,
"city": "WAYNE",
"state": "PA",
"state_display": "Pennsylvania",
"zip": null,
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "PAUL VARKI",
"contact_telephone": "+1 484-841-8202",
"dt_updated": "2020-10-23T12:09:26.927834-04:00"
},
"client": {
"id": 201602,
"url": "https://lda.senate.gov/api/v1/clients/201602/?format=api",
"client_id": 12,
"name": "ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)",
"general_description": "Registrant's name change from Egalet Corporation to Zyla Life Sciences",
"client_government_entity": false,
"client_self_select": true,
"state": "PA",
"state_display": "Pennsylvania",
"country": "US",
"country_display": "United States of America",
"ppb_state": "PA",
"ppb_state_display": "Pennsylvania",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2017-02-20"
},
"lobbying_activities": [],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
}
]
}
